Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC ...

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...

OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership EC ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS ...

Shares of CVS Health (NYSE:CVS) rose 2.8% in premarket trading on Monday following a report from the Wall Street Journal that ...

Stocks edged higher after their worst week since early September as the selloff in Treasuries abated, with traders keeping a close eye on news around President-elect Donald Trump’s administration.

HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...

Investing.com - The U.S. dollar slips slightly from the recently reached one-year high at the start of a week that is light ...

A search for a solution to the crisis in Haiti is growing more urgent as gangs gain territory and thousands more flee their homes. By Frances Robles With two months left in office, the president ...